Agile Therapeutics Inc (NASDAQ:AGRX) Expected to Announce Earnings of -$0.10 Per Share

Analysts expect Agile Therapeutics Inc (NASDAQ:AGRX) to report ($0.10) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Agile Therapeutics’ earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.14). Agile Therapeutics reported earnings per share of ($0.11) in the same quarter last year, which would suggest a positive year-over-year growth rate of 9.1%. The business is scheduled to report its next earnings report on Thursday, November 7th.

On average, analysts expect that Agile Therapeutics will report full year earnings of ($0.44) per share for the current fiscal year, with EPS estimates ranging from ($0.52) to ($0.39). For the next fiscal year, analysts expect that the company will report earnings of ($0.42) per share, with EPS estimates ranging from ($0.85) to $0.11. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.03.

AGRX has been the subject of several research analyst reports. Janney Montgomery Scott initiated coverage on shares of Agile Therapeutics in a research note on Friday, April 12th. They set a “buy” rating and a $4.00 price target for the company. ValuEngine lowered shares of Agile Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. Maxim Group set a $3.00 price target on shares of Agile Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 10th. Finally, Oppenheimer initiated coverage on shares of Agile Therapeutics in a research note on Thursday, June 6th. They set an “outperform” rating and a $5.00 price target for the company. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Agile Therapeutics presently has an average rating of “Buy” and an average price target of $4.00.

In related news, CEO Alfred Altomari purchased 20,000 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was bought at an average price of $1.27 per share, for a total transaction of $25,400.00. Following the purchase, the chief executive officer now directly owns 258,568 shares in the company, valued at approximately $328,381.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 8.50% of the company’s stock.

Hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Agile Therapeutics by 15.7% during the 4th quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock worth $77,000 after purchasing an additional 18,038 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Agile Therapeutics by 33.3% during the 1st quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock worth $630,000 after purchasing an additional 104,222 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Agile Therapeutics by 24.0% during the 4th quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 44,639 shares during the last quarter. Institutional investors own 42.38% of the company’s stock.

Shares of Agile Therapeutics stock traded down $0.11 during mid-day trading on Friday, hitting $1.00. 2,929,613 shares of the stock were exchanged, compared to its average volume of 220,383. The firm’s 50-day moving average is $1.37. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.01. Agile Therapeutics has a 12 month low of $0.23 and a 12 month high of $1.70.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Recommended Story: What is Forex?

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.